how much progress have we made in targeting kras in gi malignancies?
Published 1 year ago • 114 plays • Length 1:29Download video MP4
Download video MP3
Similar videos
-
3:20
history of kras-targeting in clinical trials
-
0:48
targeting kras in lung cancer
-
1:27
advances in the development of kras inhibitors
-
1:25
challenges of kras-targeting for lung cancer therapy
-
1:10
targeting non-g12c kras mutations in nsclc
-
5:16
mitigating resistance in kras-driven cancers
-
0:58
kras g12c inhibitors for gi cancer
-
4:09
a new era in targeting kras
-
1:55
the latest in targeted therapies for advanced colorectal cancer
-
0:41
improving outcomes in kras-mutant pancreatic cancer
-
2:39
onvansertib for second-line treatment of kras-mutated mcrc
-
2:12
advances in the management of kras-mutant nsclc
-
4:01
what are the latest developments in kras-mutant nsclc?
-
0:35
data on kras inhibitors in lung cancer at wclc 2022
-
0:41
unmet needs in kras-driven non-small cell lung cancer
-
0:51
personalized treatment approaches for patients with kras-mutant pancreatic cancer
-
1:43
survival differences in kras/braf mutations in mcrc
-
17:17
debate: targeted therapy for ras/braf wt left sided colon cancers - egfr antibodies are mandatory
-
1:18:32
advanced gi cancers: identifying and targeting uncommon but actionable genomic alterations